Stocks
Sarepta Therapeutics Financial Statements (SRPT) |
||||||||||
| Sarepta Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2020 | 01.03.2021 | 01.03.2022 | 28.02.2023 | 28.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 380.8 | 540.1 | 701.9 | 933.0 | 1 243 | 1 640 | |||
| Operating Income, bln rub | -522.3 | -564.2 | -449.7 | -536.2 | -267.8 | 81.0 | ||||
| EBITDA, bln rub | ? | -652.7 | -453.4 | -306.1 | -582.1 | -439.2 | 153.4 | |||
| Net profit, bln rub | ? | -715.1 | -554.1 | -418.8 | -703.5 | -536.0 | 121.8 | |||
| OCF, bln rub | ? | -456.5 | 107.5 | -443.2 | -325.3 | -501.0 | -352.5 | |||
| CAPEX, bln rub | ? | 62.7 | 82.2 | 38.5 | 30.8 | 76.1 | 117.9 | |||
| FCF, bln rub | ? | -519.2 | 25.3 | -481.7 | -356.2 | -588.3 | -470.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 846.6 | 1 041 | 1 055 | 1 329 | 1 361 | 1 320 | ||||
| Cost of production, bln rub | 56.6 | 63.4 | 97.0 | 140.0 | 150.3 | 239.7 | ||||
| R&D, bln rub | 560.9 | 722.3 | 771.2 | 877.1 | 877.4 | 788.1 | ||||
| Interest expenses, bln rub | 30.7 | 59.9 | 63.5 | 53.2 | 22.0 | 19.2 | ||||
| Assets, bln rub | 1 823 | 2 985 | 3 148 | 3 128 | 3 265 | 3 600 | ||||
| Net Assets, bln rub | ? | 818.2 | 761.8 | 928.0 | 385.0 | 859.3 | 1 221 | |||
| Debt, bln rub | 729.6 | 1 073 | 1 138 | 1 617 | 1 397 | 1 398 | ||||
| Cash, bln rub | 1 125 | 1 939 | 2 116 | 1 989 | 1 676 | 1 198 | ||||
| Net debt, bln rub | -395.1 | -865.7 | -977.5 | -372.0 | -279.4 | 199.2 | ||||
| Ordinary share price, rub | 129.0 | 170.5 | 90.1 | 129.6 | 96.4 | 78.0 | ||||
| Number of ordinary shares, mln | 73.6 | 78.0 | 81.3 | 87.6 | 92.4 | 95.4 | ||||
| Market cap, bln rub | 9 499 | 13 291 | 7 318 | 11 346 | 8 910 | 7 440 | ||||
| EV, bln rub | ? | 9 104 | 12 425 | 6 340 | 10 974 | 8 630 | 7 640 | |||
| Book value, bln rub | 806 | 748 | 914 | 377 | 830 | 1 221 | ||||
| EPS, rub | ? | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 1.28 | |||
| FCF/share, rub | -7.05 | 0.32 | -5.93 | -4.07 | -6.37 | -4.93 | ||||
| BV/share, rub | 10.9 | 9.60 | 11.2 | 4.31 | 8.98 | 12.8 | ||||
| EBITDA margin, % | ? | -171.4% | -83.9% | -43.6% | -62.4% | -35.3% | 9.35% | |||
| Net margin, % | ? | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 7.43% | |||
| FCF yield, % | ? | -5.47% | 0.19% | -6.58% | -3.14% | -6.60% | -6.32% | |||
| ROE, % | ? | -87.4% | -72.7% | -45.1% | -182.7% | -62.4% | 9.98% | |||
| ROA, % | ? | -39.2% | -18.6% | -13.3% | -22.5% | -16.4% | 3.38% | |||
| P/E | ? | -13.3 | -24.0 | -17.5 | -16.1 | -16.6 | 61.1 | |||
| P/FCF | -18.3 | 526.1 | -15.2 | -31.9 | -15.1 | -15.8 | ||||
| P/S | ? | 24.9 | 24.6 | 10.4 | 12.2 | 7.17 | 4.54 | |||
| P/BV | ? | 11.8 | 17.8 | 8.01 | 30.1 | 10.7 | 6.09 | |||
| EV/EBITDA | ? | -13.9 | -27.4 | -20.7 | -18.9 | -19.7 | 49.8 | |||
| Debt/EBITDA | 0.61 | 1.91 | 3.19 | 0.64 | 0.64 | 1.30 | ||||
| R&D/CAPEX, % | 894.4% | 878.7% | 2 004% | 2 845% | 1 153% | 668.3% | ||||
| CAPEX/Revenue, % | 16.5% | 15.2% | 5.48% | 3.30% | 6.12% | 7.19% | ||||
| Sarepta Therapeutics shareholders | ||||||||||
